Management Team & Board of Directors

Geneseq Biosciences’s team has extensive experience in a variety of cutting-edge technical fields including the molecular diagnostics, information technology, biotechnology, pharmaceutical and genomic industries.

Team members have demonstrated continued success in starting businesses, researching and developing novel genomic tests, launching products, building successful organisations and delivering value to stakeholders.


Ryan Van Laar Ph.D. –  Founder & CEO

Dr Ryan Van Laar received his Ph.D. in cancer genomics from the University of Melbourne (Australia)in 2007. He then worked at Agendia (Amsterdam), Regeneron Pharmaceuticals (New York) and Signal Genetics (Little Rock), before returning to Melbourne in 2016 to co-found Geneseq Biosciences. Ryan has a strong background in the translation of genomic research into robust, clinically-actionable products and services. He has helped achieve CLIA, CAP and FDA clearances for a number of high-complexity oncology tests which have provided personalized genomic information to thousands of cancer patients worldwide. In 2014, Dr Van Laar was certified as a Laboratory Director by the New York State Department of Health (Molecular and Cellular Tumor Markers). He has multiple issued patents and over 20 publications in the field of cancer genomics.


Barton Van Laar –  Co-Founder and Chairman of the Board

Barton has over 47 years experience in the Advertising, Marketing & Public Relations Industry. Specialised in Strategic Marketing, Business Planning, Advertising and Communications. He has an extensive track record in affecting organisational and governmental change in addition to managing community relations. Barton has managed, advised and invested in a number of successful early-mid stage companies across a range of sectors. 


Melinda McGrath BSc BA MBA –  Board Member

Melinda is the Chief Executive Officer and Managing Director of Australian Clinical Labs and has more than 20 years’ experience in Chief Executive roles in the hospital and pathology industries. Melinda holds a degree in science, a Bachelor of Arts degree (psychology) and an MBA. She has been a Board member of several organisations, including Metro North Health and Hospitals Service (Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services); and UC Super, a superannuation company.


James Davison BBus CPA – Board Member

James is the Chief Financial Officer and Company Secretary of Australian Clinical Labs where he is responsible for finance, planning, reporting and governance. James’ areas of expertise include acquisitions and divestments, financial and strategic management and operational efficiency, which were developed in a career spanning more than 17 years in the health industry. His previous roles include GM Finance Pathology – Australia & International at Healthscope; CFO of Australia Diagnostics Group and GM Finance at Symbion Health. James holds a Bachelor of Business degree from Swinburne University and is a CPA.


Ingrid Winship MBChB, MD, FRACP, FACD, FAICD – Board Member

Prof Winship is a graduate of the University of Cape Town, dual trained in Clinical Genetics and Dermatology. In 2006 she became the Inaugural Chair of Adult Clinical Genetics at the University of Melbourne and The Royal Melbourne Hospital. She was also at this time appointed as Melbourne Health’s Executive Director of Research and during her 12-year tenure launched the Clinical Trials Research Centre in the city campus. Professor Winship is currently a member of the Victorian Cancer Agency Reference Group and a Director of the Boards of the Australasian College of Dermatologists, the Australian Genome Research Facility and Global Variome. She is Chair of the Australian Health Ethics Committee and a member of the Health Research Strategy External Advisory Group for New Zealand.